Aquestive Therapeutics, Inc. (AQST) · Oct 15, 2026 · Other events

Aquestive FDA acceptance puts Anaphylm on March 2027 approval clock

FDA acceptance — Class 2 resubmission; PDUFA date March 16, 2027

Aquestive’s FDA acceptance of the Anaphylm resubmission creates a defined March 2027 decision date, but does not resolve approval risk.

Aquestive is centered on Anaphylm, its lead regulatory and commercial catalyst: after receiving a January 2026 Complete Response Letter focused on human-factors and supportive pharmacokinetic issues, the company completed corrective studies and had already planned a third-quarter 2026 resubmission.

The FDA has accepted the resubmission as complete and set a decision date. The filing confirms a Class 2 response and a PDUFA goal date of March 16, 2027. 〔0〕 This is meaningful because the application is now back under formal FDA review rather than sitting in a post-CRL remediation phase.

The update is confirmation more than surprise. Aquestive had already disclosed positive human-factors and PK results, reaffirmed a third-quarter resubmission target, and indicated that a typical review could take about six months; the company itself describes the Class 2 outcome as expected. The new information is the precise FDA classification and March 16, 2027 action date, not a new efficacy result or a regulatory endorsement of approval.

The central approval risk remains intact. FDA acceptance means the submission is complete for review; it does not mean the agency agrees that the January CRL deficiencies have been fully resolved. The filing expressly says the FDA could request additional information, studies, or analyses, and could disagree with the company’s interpretation of the new data. 〔1〕

International progress remains a secondary near-term milestone. The company says it remains on track to submit its Canadian New Drug Submission in the fourth quarter of 2026. 〔2〕

Bottom line: This moves Anaphylm from remediation back into a defined FDA review process, which removes timing uncertainty but does not materially reduce the ultimate approval uncertainty. The event is therefore a useful confirmation of the expected path, not a clean regulatory win.

What to watch next

Canadian NDS submission, Q4 2026

Original filing on SEC EDGAR

More Aquestive Therapeutics, Inc. news

Aquestive FDA acceptance puts Anaphylm on March 2027 approval clock | AQST Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.